AVISAR™ System

The AVISAR™ System represents a quantum leap forward in providing a sensitive technology for detecting respiratory infections and other metabolic diseases.

The AV-BreathTest™ is based on the presence of the enzyme, urease, which is found in many bacterial species that cause lung infections, such as Mycobacterium tuberculosis.
The AV-BreathTest™ uses a solution containing13C-urea, AV-U13, that is ready for administration with the nebulizing device.
The AVISAR SPEC™ laser spectrometer incorporates major design advances that have resulted in a highly portable, battery operated detection device that will have enormous utility in point-of-care settings.
The AVISAR SPEC™ is a rugged, portable device that rapidly measures breath13CO2/12CO2 isotopic ratios.
Learn More

Global Unmet Need for Better TB Diagnostics

TB-home

  • Tuberculosis (TB) continues to be a major worldwide health problem with over 9 million new cases in 2012 and 1.3 million deaths.

  • TB is highly contagious making timely diagnosis critical not only for patient treatment, but also for implementation of infection control measures to prevent further spread.

  • The universal challenge that limits the successful treatment of these diverse patient groups is the lack of non-sputum point-of-care technologies that can rapidly detect when a patient has a respiratory infection that requires further triage.

Learn More

Meet Our Team

David S. Joseph
Co-Founder, President, CEO & Chairman
Graham S. Timmins, Ph.D.
Chief Science Advisor
Elizabeth A. Perkett, M.D.
Chief Medical Officer
Carol LaRotonda
CFO
David Karshmer
VP, Technology Development
John Maynard
VP, Engineering
Learn More

Latest from the Newsroom